Austin, Texas, United States, August 4th, 2026, FinanceWire
SRX Global (NYSE American: SRXH) announced that it has acquired a stake in Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company developing intranasal neuroscience therapies based on its proprietary pherine platform. SRX said the investment aligns with its strategy of creating long-term shareholder value through investments in high-conviction operating companies and strategic assets.
SRX said it believes Vistagen shares are undervalued and intends to engage constructively with the company’s leadership team and board of directors to discuss opportunities to unlock shareholder value.
To view the full press release, visit https://ibn.fm/NEczV
About SRX Global Inc.
SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors.
For more information on the company, please visit: www.SRXGlobalInc.com
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer